期刊文献+

唑来膦酸注射液治疗骨质疏松的疗效观察 被引量:1

原文传递
导出
摘要 目的观察唑来膦酸注射液抗骨质疏松的疗效。方法选取2018年6月至2020年6月郑州大学第五附属医院90例骨质疏松患者为研究对象,根据随机数字表法分为对照组(30例)与观察组(60例)。对照组给予基础治疗,观察组给予基础治疗联合唑来膦酸注射液治疗。比较两组骨密度和骨代谢标志物变化。结果治疗前,两组患者骨密度比较差异未见统计学意义(P>0.05)。治疗后,对照组骨密度值下降,其中腰椎骨密度值变化有统计学意义(P<0.05);颈部骨密度值变化差异未见统计学意义(P>0.05);观察组腰椎及颈部骨密度值增加,差异均有统计学意义(P<0.05)。治疗前,两组血清骨钙素、P1NP、β胶原特殊序列水平比较差异未见统计学意义(P>0.05)。治疗后两组骨钙素、P1NP水平比较差异未见统计学意义(P>0.05),β胶原特殊序列水平在对照组略有升高,差异未见统计学意义(P>0.05),观察组明显下降,差异有统计学意义(P<0.05),两组比较差异有统计学意义(P<0.05)。结论唑来膦酸注射液可改善骨密度、降低β胶原特殊序列水平。
作者 宋淑敏
出处 《临床医学》 CAS 2021年第2期98-100,共3页 Clinical Medicine
  • 相关文献

参考文献6

二级参考文献50

  • 1孟迅吾;徐苓.骨质疏松症和骨矿盐疾病诊疗指南[J]骨质疏松症基础与临床,2006(34):155-167.
  • 2Neville-Webbe HL,Coleman RE. The use of zoledronic acid in the management of metastatic bone disease and hypercalcaemia[J].Palliative Medicine,2003,(06):539-553.
  • 3Chapurlat RD. Single annual injectable treatment for postmenopausal osteoporosis[J].Expert Opin Drug Deliv,2008,(05):583-591.
  • 4Li EC,Davis LE. Zoledronic acid:a new parenteral bisphosphonate[J].Clinical Therapeutice,2003,(11):2669-2708.
  • 5Cheer SM,Noble S. Zoledronic acid[J].DRUGS,2001,(06):799-805,806.
  • 6Reid DM,Devogelaer JP,Saag K. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON):a multicentre,double-blind,double-dummy,randomised controlled trial[J].LANCET,2009,(9671):1253-1263.
  • 7Lin H,Bao LH,Zhu XF. Analysis of recurrent fracture of a new vertebral body after precutaneous vertebroplasty in patients with osteoporosis[J].Orthop Surg,2010,(02):119-123.
  • 8Melika H, Stephens, Andrew Grey, et al. 3-D bone models to improve treatment initiation among patients with osteoporosis: A randomised controlled pilot trial. Psychology & Health,2016,31 (4) :487-497.
  • 9Akira Itabashi, Kousei Yoh, Arkadi AC, et ah Bridging analysis of the efficacy and safety of bazedoxifene in Japanese and global populations of postmenopausal women with osteoporosis. Journal of Bone and Mineral Metabolism ,2015,33 ( 1 ) :61-72.
  • 10Chen JF,Tang KH, Zhang ZL, et ah A systematic review on the use of daily subcutaneous administration of teriparatide for treatment of patients with osteoporosis at high risk for fracture in Asia. Osteoporosis International,2015,26 ( 1 ) : 11-28.

共引文献401

同被引文献10

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部